(UroToday.com) Erdafitinib is a pan-fibroblast growth factor receptor (FGFR) inhibitor that is approved in adult patients with locally advanced urothelial carcinoma or metastatic urothelial carcinoma and susceptible FGFR3/2 alterations following ≥1 line of platinum-based chemotherapy. Approval of erdafitinib was based on data from the primary analysis of the pivotal BLC2001 trial in adult patients with previously treated locally advanced or metastatic urothelial carcinoma and FGFR3/2 alterations.1 At the final analysis of the BLC2001 study, among all patients treated with the optimal schedule of erdafitinib, the objective response rate was 40%, the median duration of response was 5.98 months, median progression-free survival was 5.5 months, and median overall survival was 11.3 months. At the virtual 2020 European Society of Medical Oncology (ESMO) annual meeting, Dr. Andrea Necchi and colleagues report on subgroup analyses of efficacy outcomes after a median two years of treatment with erdafitinib.